"Aspirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Descriptor ID |
D001241
|
MeSH Number(s) |
D02.455.426.559.389.657.410.595.176
|
Concept/Terms |
Aspirin- Aspirin
- Acetylsalicylic Acid
- Acid, Acetylsalicylic
- 2-(Acetyloxy)benzoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Aspirin".
Below are MeSH descriptors whose meaning is more specific than "Aspirin".
This graph shows the total number of publications written about "Aspirin" by people in this website by year, and whether "Aspirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 2 | 2 |
1996 | 1 | 0 | 1 |
1998 | 2 | 2 | 4 |
1999 | 0 | 1 | 1 |
2000 | 0 | 3 | 3 |
2001 | 0 | 2 | 2 |
2002 | 2 | 2 | 4 |
2003 | 1 | 1 | 2 |
2004 | 1 | 1 | 2 |
2005 | 2 | 2 | 4 |
2006 | 2 | 1 | 3 |
2007 | 1 | 1 | 2 |
2008 | 4 | 1 | 5 |
2009 | 3 | 1 | 4 |
2010 | 3 | 2 | 5 |
2011 | 0 | 2 | 2 |
2012 | 5 | 1 | 6 |
2013 | 1 | 0 | 1 |
2014 | 1 | 3 | 4 |
2015 | 5 | 2 | 7 |
2016 | 1 | 1 | 2 |
2017 | 2 | 1 | 3 |
2018 | 2 | 2 | 4 |
2019 | 2 | 2 | 4 |
2020 | 4 | 1 | 5 |
2021 | 6 | 3 | 9 |
2022 | 1 | 4 | 5 |
2023 | 1 | 8 | 9 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aspirin" by people in Profiles.
-
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e026921.
-
Editors' Note: IV Thrombolysis vs Early Dual Antiplatelet Therapy in Patients With Mild Noncardioembolic Ischemic Stroke. Neurology. 2024 Mar 12; 102(5):e209236.
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024 Jan 01; 47(1):81-88.
-
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology. 2023 Nov 27; 101(22):e2205-e2214.
-
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2023 11 01; 8(11):1061-1069.
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. J Am Heart Assoc. 2023 10 17; 12(20):e030385.
-
Use of nonsteroidal anti-inflammatory drugs and poor olfaction in women. Int Forum Allergy Rhinol. 2024 Mar; 14(3):639-650.
-
Mortality in Patients Hospitalized With Acute Myocardial Infarction Without Standard Modifiable Risk Factors: The ARIC Study Community Surveillance. J Am Heart Assoc. 2023 07 04; 12(13):e027851.
-
Internet Versus Noninternet Participation in a Decentralized Clinical Trial: Lessons From the ADAPTABLE Study. J Am Heart Assoc. 2023 07 04; 12(13):e027899.
-
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. Am Heart J. 2023 10; 264:31-39.